Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
暂无分享,去创建一个
S. Larson | H. Kalaigian | R. Tuttle | K. Kolbert | R. Robbins | M. Sonenberg | W. Wang | Weiping Wang
[1] J. Hanke,et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] B. Caillou,et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. , 1986, The Journal of clinical endocrinology and metabolism.
[3] J. Nicoloff,et al. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. , 1999, Thyroid : official journal of the American Thyroid Association.
[4] T. Shiga,et al. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] J. Llamas-Elvira,et al. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. , 2000, American journal of surgery.
[6] S M Larson,et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding , 1997, Cancer.
[7] S. Larson,et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. , 2000, The Journal of clinical endocrinology and metabolism.
[8] R. Wahl,et al. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. , 1993, The Journal of clinical endocrinology and metabolism.
[9] H. Maxon,et al. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. , 1997, Thyroid : official journal of the American Thyroid Association.
[10] E. Mazzaferri. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. , 1997, Thyroid : official journal of the American Thyroid Association.
[11] J. Aronstein,et al. Environmental conditions of residential electrical connections , 1998, Electrical Contacts - 1998. Proceedings of the Forty-Fourth IEEE Holm Conference on Electrical Contacts (Cat. No.98CB36238).
[12] J. D. Lin,et al. Expression of sodium iodide symporter in metastatic and follicular human thyroid tissues. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] H. Joensuu,et al. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] S. Larson,et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.
[15] J. Robbins. Management of thyroglobulin-positive, body scan-negative thyroid cancer patients: Evidence for the utility of I-131 therapy , 1999, Journal of endocrinological investigation.
[16] V. Lazar,et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. , 1999, The Journal of clinical endocrinology and metabolism.
[17] J. Hanke,et al. [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I]. , 1995, Nuklearmedizin. Nuclear medicine.
[18] E. Baudin,et al. 131I therapy for elevated thyroglobulin levels. , 1997, Thyroid : official journal of the American Thyroid Association.
[19] G. Johnston,et al. Radioiodine therapy for thyroid cancer. , 1995, Endocrinology and metabolism clinics of North America.
[20] G Sgouros,et al. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] M. Sonenberg,et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.
[22] R Mohan,et al. Three-dimensional dosimetry for radioimmunotherapy treatment planning. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] R. Leeper. The Effect of 131I Therapy on Survival of Patients with Metastatic Papillary or Follicular Thyroid Carcinoma , 1973 .
[24] M. Schlumberger,et al. Papillary and follicular thyroid carcinoma. , 1998, The New England journal of medicine.